You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Proto-Oncogene Proteins B-raf

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Adenocarcinoma, Lung Cancer Trial in Truro (Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF

Unknown status
  • Pancreatic Adenocarcinoma
  • Lung Cancer
  • Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples
  • Truro, Cornwall, United Kingdom
    Royal Cornwall Hospital
Feb 26, 2021

Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer Trial in United Kingdom (NX-1607)

Recruiting
  • Ovarian Cancer, Epithelial
  • +14 more
  • Sutton, Surrey, United Kingdom
  • +6 more
Jul 22, 2022

BRAF V600E, Metastatic Colorectal Cancer Trial in China (Encorafenib, Cetuximab, FOLFIRI)

Recruiting
  • BRAF V600E
  • Metastatic Colorectal Cancer
  • Beijing, Beijing, China
  • +33 more
Dec 20, 2022

Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma Trial in United States

Active, not recruiting
  • Stage III Cutaneous Melanoma AJCC v7
  • +2 more
  • Computed Tomography
  • +3 more
  • Birmingham, Alabama
  • +759 more
Aug 18, 2022

Melanoma, Glioma, Thyroid Cancer Trial (PF-07799544, PF-07284890, PF-07799933)

Not yet recruiting
  • Melanoma
  • +6 more
  • (no location specified)
Sep 9, 2022

Solid Tumor, Haematological Malignancy, Melanoma Trial in United Kingdom (Vemurafenib, Cobimetinib)

Recruiting
  • Solid Tumor
  • +11 more
  • Belfast, United Kingdom
  • +16 more
Mar 2, 2023

BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

Completed
  • BRAF V600E Unresectable or Metastatic Melanoma
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 9, 2022

Low-grade Glioma, Plexiform Neurofibroma, CNS Glioma Trial in Canada (Trametinib)

Active, not recruiting
  • Low-grade Glioma
  • +2 more
  • Calgary, Alberta, Canada
  • +6 more
Oct 25, 2022

Malignant Melanoma, NSCLC, Brain Tumors, Primary Trial in United States (PF-07284890, Binimetinib, Midazolam)

Recruiting
  • Malignant Melanoma
  • +4 more
  • Duarte, California
  • +71 more
Dec 29, 2022

Stage IV Melanoma, Stage III Melanoma Trial in Jette (Trametinib, Dabrafenib)

Recruiting
  • Stage IV Melanoma
  • Stage III Melanoma
  • Jette, Brussels, Belgium
    Universitair Ziekenhuis Brussel
Sep 29, 2021

Lymphoma, Large B-Cell, Diffuse, Burkitt Lymphoma Trial (Gallium citrate)

Withdrawn
  • Lymphoma, Large B-Cell, Diffuse
  • Burkitt Lymphoma
  • Gallium citrate
  • (no location specified)
Oct 8, 2019

Resistance-associated Mutations in Metastatic Lung Cancer

Recruiting
  • Lung Cancer
  • Liquid biopsy
  • Monza, MB, Italy
    Fondazione IRCCS San Gerardo dei Tintori
Oct 10, 2023

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

28 Day Mortality Trial (no intervention)

Recruiting
  • 28 Day Mortality
  • no intervention
  • Nanjing, Jiangsu, China
    Zhongda Hospital, Southeast University
Nov 25, 2022

NSCLC Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1) Trial in Boston (SBRT with protons or photons)

Active, not recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Targetable Oncogenes (EGFR, ALK, ROS1)
  • SBRT with protons or photons
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 22, 2021

Called STAR-T to Learn More About Sequential Treatment With

Not yet recruiting
  • Metastatic Colorectal Cancer (mCRC)
  • Regorafenib (BAY73-4506, Stivarga®)
  • +2 more
  • Whippany, New Jersey
    Many locations
Apr 21, 2023

Melanoma, Solid Tumor Trial in Korea, Republic of, Spain, United States (DAY101, Pimasertib Hydrochloride)

Recruiting
  • Melanoma
  • Solid Tumor
  • Los Angeles, California
  • +13 more
Jul 27, 2022

Biliary Tract Carcinoma Trial in Shanghai (Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab)

Recruiting
  • Biliary Tract Carcinoma
  • Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 25, 2022

Langerhans Cell Histiocytoses Trial in Barcelona

Recruiting
  • Langerhans Cell Histiocytoses
    • Barcelona, Spain
      Hospital de la Santa Creu i Sant Pau
    Aug 16, 2020

    Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma Trial in United States (trametinib, laboratory biomarker analysis,

    Completed
    Has Results
    • Recurrent Melanoma
    • +3 more
    • Washington, District of Columbia
    • +3 more
    May 4, 2021

    Metastatic Colorectal Cancer Trial in France (Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, Panitumumab, oxaliplatin,

    Recruiting
    • Metastatic Colorectal Cancer
    • Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil
    • Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan
    • Avignon, France
    • +5 more
    Aug 2, 2022

    Resectable Early-stage Non-small Cell Lung Cancer

    Completed
    • Non-small Cell Lung Cancer
      • Alexandria, Egypt
      • +3 more
      Nov 21, 2022

      Non Small Cell Lung Cancer Trial in Seoul (sotorasib)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Jul 5, 2022

      Glioblastoma, Recurrent Glioblastoma Trial in Atlanta (Avutometinib, Biospecimen Collection, Defactinib)

      Not yet recruiting
      • Glioblastoma
      • Recurrent Glioblastoma
      • Atlanta, Georgia
        Emory University Hospital/Winship Cancer Institute
      Mar 22, 2023

      KCTD Protein Family in Clinical Management of Childhood Acute

      Recruiting
      • Childhood Acute Lymphoblastic Leukemia
      • observational study
      • Naples, Italy
        IRCCS Synlab SDN
      Feb 6, 2023